Seeking Alpha

Arrowhead Research (ARWR) +5.3% premarket after a study of its RNAi-based candidate ARC-520 in a...

Arrowhead Research (ARWR) +5.3% premarket after a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus supports findings from rodent models indicating it can knock down hepatitis B virus DNA and key viral antigens.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs